Heron Therapeutics (FRA:AXD2) FFO


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.38
GF Value €1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.38 is trading 73.1% below its estimated GF Value™ of €1.40. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • FFO:
  • GF Value™: €1.40 vs. price of €0.38 (73.1% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€1.40
GF Value